Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.

ABSTRACT:

Background

The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.

Methods

In an ongoing phase 3 trial, we enrolled adults (≥18 years of age) who had an increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one contai

SUBMITTER: Levin MJ 

PROVIDER: S-EPMC9069994 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature